option for delicate or complex anatomic areas. The techniques described should permit experienced injectors to artfully and safely design customized injectable regimens for patients.
NeuROMOdulatORS Scientific Background
Aesthetic neuromodulation with botulinum toxin type A is the most commonly performed cosmetic procedure in the United States, with 6.7 million injections performed in 2014.
1 Currently, there are 3 FDA-approved botulinum toxin type A formulations: onabotulinumtoxinA (Botox; Allergan), abobotulinumtoxinA (Dysport; Galderma), and incobotulinumtoxinA (Xeomin; Merz Pharmaceuticals). All 3 are derived from the Clostridium botulinum toxin and act at the neuromuscular junction to paralyze muscles by cleaving synaptosomal-associated protein 25 that facilitates acetylcholine vesicular release. 2 Although all 3 toxins cause muscle paralysis, they differ in their preparation, mechanism of action, storage, dilution, and dosing [3] [4] [5] (Table 1) . Despite these distinctions and anecdotal observations that these products are not interchangeable, clinical studies remain inadequate and have failed to demonstrate consistent substantive differences between neurotoxins. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Limited data suggest that incobotulinumtoxinA has a more rapid onset and longer duration, 10 whereas abobotulinumtoxinA has greater spread, 11 and onabotulinumtoxinA has greater strain reduction. 12 Importantly, all neurotoxins elicit similar positive effects on patients' self-perception of appearance. 13 The authors consider that the 3 neurotoxins do behave slightly differently in the clinical setting and that strategically tailored dilutions of a given product may be superior in specific anatomic sites and in specific patients.
Refinements in Clinical Neuromodulator application Upper Face
Techniques of neuromodulation of the upper face, consisting of the frontalis, corrugator, procerus, orbicularis oculi, and nasalis muscles, have rapidly evolved. The optimal treatment of the upper face is presented in Figure 1 and Table 2 . The ideal patient is one without static rhytids, brow or eyelid ptosis, and severe volume atrophy of the upper face. Patients must be educated about the need to treat the entire anatomic region synergistically to avoid unnatural effects. Treatment goals should be to undercorrect and allow subtle motion and expression. The selection of a particular neuromodulator should be based upon the injector's experience and the patient's anatomy.
Perioral Area
Neuromodulation of the perioral region presents a unique anatomic challenge. The goal of neuromodulation in this region is to both prevent and soften perioral rhytids. In addition, physicians seek to improve the shape and motion of the perioral complex while preserving smiling, mastication, and articulation. Given this fine balance, neuromodulation of the perioral region should be undertaken by experienced injectors after extended discussions with patients about expected changes in perioral motion. The ideal patient demonstrates either early dynamic vertical rhytids, depression of the oral commissures secondary to overactive depressor anguli oris activity, or a "gummy smile" secondary to hyperactivity of the "Yonsei point," at the intersection of the 3 lip levators. Lip sphincter, elevator, and depressor balance must be meticulously characterized in relation to underlying bony structure, dentition, and occlusion before treatment. None of the currently available neurotoxins are FDA approved for perioral injection.
Neuromodulation of the perioral region requires a precise understanding of perioral anatomy. In this region, the authors prefer neurotoxins prepared with high dilution volumes using the lowest possible dosing as given in Table 3 . (See figure, Supplemental digital Content 1, which shows the optimal treatment of neurotoxin: pattern of injection, http://links.lww.com/PRSGO/A333.)
Jawline and Neck
Neuromodulation of the jawline and neck can significantly improve the shape and motion of the lower facial region. The authors have developed the following principles in the treatment of this area: (1) A higher reconstitution volume of 4 mL with onabotulinumtoxinA utilizing closely spaced injection sites produces a more natural outcome; (2) platysmal bands in addition to horizontal neck creases are treated by multilevel superficial injections using a microdroplet technique 23 ; (3) the combination of a deeper injection at the muscle origin and a more superficial injection at the muscle insertion to the overlaying skin delivers a more precise result; (4) 
Refinements in Clinical application
The authors propose that the 2 anatomic areas of the face that benefit most from technical refinements of HA injections are the periocular and perioral regions. Both sites are anatomically complex with tremendous differences in tissue quality within and between patients. Injections of the periorbital area must consider the complex interplay between the bony structures of the orbit in relation to the delicate superficial tissues and malars in a largely adynamic zone, whereas perioral injections must consider the complex interplay between the lip mucosa and thicker surrounding superficial tissues in relation to the highly dynamic perioral musculature and underlying bony structure and dentition. The most critical modification of HA injection of these sites is the blending of the product with normal saline or lidocaine and epinephrine (in a 0.02-1:1 ratio) to soften rheological properties, increase ease of injection, and decrease the risk of contour abnormalities. 
Periocular Rejuvenation
The periorbit is a highly desirable target for filler injections, as proper treatment of the area can dramatically rejuvenate the entire face. 29 Both the upper and lower orbits must be considered in all patients.
1. Tear trough and lower eyelid: Younger patients frequently complain about the tear trough deformity. 30 This presents as thin skin and orbicularis over the bony lower orbital rim. Older patients present with more complex contour deformities and loss of tissue integrity of the entire lower periorbit.
• Patient selection: The ideal patient to treat has a clear tear trough demarcation, usually hereditary, with little lower eyelid fat and good skin and muscle tone (Fig. 1 of its hydrophilicity. 31 Belotero is a good choice and can be placed more superficially than other fillers.
• Injection technique: Injection safety is a major consideration for periocular rejuvenation. A clear understanding of facial anatomy is critical to avoid a catastrophic complication, such as inadvertent vessel cannulation. The principal facial foramina and large periocular vessels can be accurately localized using the patient's pupil as a global positioning system: the supraorbital vessels are aligned with the medial iris limbus, and the infraorbital vessels fall between the pupil and the medial iris [32] [33] [34] (Fig. 4) . The infraorbital hollows should be injected at the supraperiosteal level using needles of 29-G to 30-G or cannula of 27-G to 29-G. Needles deliver more precise implant placement, whereas cannula reduces bruising and swelling. • Patient selection: The ideal patient presents with a deep upper eyelid sulcus due to involutional changes or aggressive fat subtraction blepharoplasty (Fig. 5) . Less commonly, a younger patient may present with a congenital deep upper eyelid sulcus or periocular fat wasting from excessive exercise or weight loss (Fig. 6 ). The less ideal patient is one with significant fat prolapse, dermatochalasis, brow ptosis, chronic periocular edema, and/or poor skin and muscle tone. For such a patient, surgery is a better choice. • Product selection: Because upper eyelid skin is the thinnest in the body, 38 any injection may result in visible irregularities. Belotero Balance is a good option for this region. The authors prefer pure Belotero Balance or blended Restylane or Juvéderm Ultra XC (1 mL product mixed with 0.3 to 0.5 mL lidocaine 1% with or without epinephrine) in older, thin skin patients. In younger patients with good skin tone, the authors prefer nonblended products.
• Injection technique: The authors recommend cannula injection in the upper eyelid for optimal safety. The injection should be in the suborbicularis plane below the orbital rim. One must take into consideration that the supraorbital vessel is aligned with the medial iris limbus, and the supratrochlear is slightly more medial (Fig. 4) 
Perioral Rejuvenation
Perioral rejuvenation extends beyond isolated "barcode" perioral rhytid treatment, vermilion enhancement, or lip augmentation and should encompass structural enhancement of the entire perioral complex, from the alar bases to the oral commissures and marionette lines. The goal of perioral rejuvenation is to restore and improve the natural youthful lip contour without distorting shape and key anatomic features.
• Patient selection: The ideal patient has normal occlusion without maxillary or mandibular bony absorption and presents with mild volume loss of the lip, vermillion border, and oral commissures with subtle vertical rhytids that are not fully imprinted. Patients with severe static perioral rhytids, congenital thin lips, severe perioral volume atrophy, moderate-to-severe jowling, and thick heavy faces are poor injectable candidates.
• Patient evaluation: The alar bases, nasolabial folds, vermilion border, vermillion, cutaneous lip, oral commissures, and marionette lines must be evaluated for potential volume loss and lack of definition. Severe static perioral "barcode" rhytids are notoriously difficult to treat with fillers alone and may require synergistic neuromodulation and/or skin resurfacing. • Product selection: Currently, all HA fillers are approved for nasolabial fold treatment, but only 2 products are specifically approved for lip volumization, Juvéderm Ultra XC, and Restylane Silk (Galderma). As in other areas, the authors advocate for product selection that matches the patient's tissue. A patient with deep, thick nasolabial folds or sunken prejowl sulci may benefit from Juvéderm Voluma XC or Restylane Lyft, whereas the application of Belotero Balance may not produce adequate correction. For the lip itself, Restylane Silk, Restylane-L (Galderma), and Belotero Balance represent the author's preferred products that are applied without blending. Anecdotal reports exist of increased swelling with Restylane Silk. This has prompted some injectors to prescribe prophylactic oral steroids. • Injection technique: Technique is largely dependent on practitioner experience, target region, and product selected. Both cannula and needle may be employed. Treatment of the nasolabial folds and marionettes is extensively discussed in other publications. For enhancement of the lip, product may be threaded along the wet dry junction and/or the white roll. Additional product may be placed into the lip mucosa and Cupid's bow for final shaping. Undercorrection is 
Scientific Background
Poly-L-lactic acid (PLLA) is not a traditional soft-tissue filler but rather a biostimulatory agent. The mechanism of action of PLLA involves the stimulation of a subclinical inflammation after which recipient site produces Type I collagen for up to 24 months after injection. 39 The end result includes volume restoration, increase in skin thickness, and improvement in soft-tissue texture. 40 Recently, a consensus group of experts recommended the best practice guidelines for predictability in volume augmentation using PLLA with minimal adverse events. 41 
Refinements in Clinical application
The resulting major refinements in PLLA injection are summarized in Table 5 . Video Graphic 3. see video, supplemental digital content 6, which demonstrates upper eyelid, eyebrow (rooF), and temporal fossa injections, available in the "related Videos" section of the full-text article on PrsJournal.com or, for ovid users, at http://links.lww.com/ PRSGO/A338.
Table 5. Comparison of Sculptra Consensus Recommendation and Author Preferences
Step
Consensus Recommendation author Preferences
Reconstitution/dilution Slowly add 7-8 mL sterile water for injection or bacteriostatic water Slowly add 7 mL sterile water for injection or bacteriostatic water Hydration Hydrate at room temperature for ≥24 h Hydrate at room temperature for ≥48 h Final injection volume for facial treatment 9 mL, achieved by the addition of 1-2 mL lidocaine (with or without epinephrine) immediately before injection 
Decollete and Buttock Rejuvenation
Other described uses of PLLA are hand rejuvenation, chest/décolleté, and buttock 43, 44 (Fig. 8) . Variation of reconstitution depends on treatment area [45] [46] [47] (Table 6 ). Patient Selection and Injection Technique. The most critical modification of PLLA injection of these sites is the hyperdilution of the product (>7 mL per vial) and extended product hydration (>1 wk).
SOFt-tISSue FIlleRS: CalCIuM HYdROXYlaPatIte (RadIeSSe, MeRz, uS) Scientific Background
Calcium hydroxylapatite (CaHA), composed of synthetic CaHA microspheres suspended in an aqueous carboxymethylcellulose gel carrier, was introduced in 2006 as a dermal filler for facial wrinkles and folds 25 and was approved for hand rejuvenation in 2015. [48] [49] [50] [51] [52] [53] Although CaHA fillers are generally well tolerated, they can produce increased injection-site reactions and granuloma formation when compared with HA fillers 54, 55 and should be utilized by experienced injectors in the appropriate applications.
56,57

Refinements in Clinical application
The recent introduction of longer lasting HA fillers with greater lifting power in the context of residual inflammatory scarring in surgical areas previously treated with CaHA injections has led to a shift in CaHA applications. The authors' preference is to use CaHA specifically for the volumization of deep supraperiosteal regions that are not dissected during standard surgical rejuvenation of the face and for subcutaneous hand rejuvenation.
Facial Volumetric Augmentation
The ideal patient presents with discrete volume loss requiring volumetric augmentation, rather than superficial line filling. Either needles or cannulas can be used. Ideal zones for supraperiosteal injection are mental protuberance, prejowl sulcus, temporal fossa, mandibular angle, and alar bases. The most critical modification of CaHA injection of these sites is the blending of the product with normal saline or lidocaine and epinephrine (in a 0.02-1:1 Fig. 8 . Left chest volume restoration after implant removal. three sessions, 1 vial per session, reconstitution 7 mL sterile water, 2 mL Xilocaine 1% with epinephrine plus 2 mL Bupivacaine 0.05% (total vial volume, 11 mL). A, before first session; (B) after second session. ratio) to soften its rheological properties and increase ease of injection. The authors recommend microbolus injections (0.1-0.3 mL) to avoid overfilling as CaHA dissolution cannot be achieved with hyaluronidase.
Hand Rejuvenation
CaHA has distinct advantages over the other fillers in the hand because of its white color that provides a concealing effect over veins and tendons and its malleability. 58 The authors recommend the use of blended CaHA for hand volumization with lidocaine 1% to 2%, 0.1 to 1 mL per CaHA syringe, to decrease pain and viscosity [58] [59] [60] [61] [62] [63] [64] [65] [66] (Table 7) . Either needles or cannulas may be safely 65 utilized, with the benefit of a single entry point with cannulas. (See video, Supplemental digital Content 11, which demonstrates hands Radiesse cannula injection, available in the "Related Videos" section of the full-text article on PRSJournal.com or, for Ovid users, at http://links.lww.com/PRSGO/A343.) Increased adverse effects are associated with higher volumes injected. 60 The authors agree with the current recommendations not to exceed 3 mL of CaHA per hand 60 (Table 7) .
CONCluSIONS
The field of facial aesthetics has evolved dramatically over the past 2 decades. Our increased understanding of 3-dimensional structural volume restoration in combination with the continuous development of novel injectable products with distinct properties has stimulated this evolution. Consequently, it has become critically important to understand not just the basic technical approaches to volumization and neuromodulation but more importantly the unique nuances of patients' tissues in relation to innate product characteristics and the potential to modify the latter to match the former. Blending or "customizing" injectable products with anesthetic agents or other diluents can often result in a better outcome for complex areas, such as the periorbital and perioral areas, hands, and décolletage. 43 26-G needle 43 8-10 mL dilution per vial (6 mL SWFI + 2 mL of 1% lidocaine) 44 25-G needle 44 14 mL (5 mL SWFI and 9 mL lidocaine HCl 1%) 47 25-G needle or cannula 47 10 mL (9 mL of bacteriostatic sterile water plus 1 mL 1% lidocaine without epinephrine) 67 25-or 27-G needle 44 Chest/décolleté 10 mL of sterile water 45 27-G needle 45 24 mL (5 mL SWFI and 19 mL lidocaine HCl 1%) 47 27-G needle 47 Buttock 12 mL (5 mL SWFI and 7 mL lidocaine 1%) 47 
25-G needle or cannula 47
Video Graphic 4. see video, supplemental digital content 11, which demonstrates radiesse cannula injection into the hands, available in the "related Videos" section of the full-text article on PrsJournal.com or, for ovid users, at http://links.lww.com/PRSGO/A343. In addition, recent patient-perceived outcome data suggest that product customization may be important in specific patient populations. For example, older patients may perceive more of a benefit from full neuromodulator correction, whereas men and younger women may prefer undercorrection. 8 Recent novel data confirming differential strain reduction patterns among the 3 neurotoxins further support customized treatments within and between patients. 9 The authors reviewed current FDA-approved injectables and described how, through clinical experience, product modification can produce safe and natural results with excellent patient outcomes. We provided our recommendations for subtle alterations in product profiles in discrete anatomic sites for both inexperienced and experienced injectors. The incorporation of these customized techniques will enable cosmetic practitioners to produce refined individualized results for the increasingly discerning cosmetic patient population.
Complications and adverse events with injectables can be prevented in most cases. Nevertheless, every patient is advised of these uncommon events and most accept the risk by affixing their signature to consent (Table 8) . 
